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Transglutaminase 2 (TG2) is a multifunctional protein that can perform 
functions as transglutaminase, protein kinase, cell surface adhesion mediator, G 
protein, protein disulfide isomerase and isopeptidase depending on stimuli. 
Several studies have shown the effect of transglutaminase 2 on bone formation. 
TG2 has been reported to be required for fibronectin and type I collagen matrix 
deposition. However, functions of TG2 in bone metabolism still remain unclear 
and TG2 has not yet been examined in osteoclastogenesis.  
Therefore, this study was carried out to clarify whether TG2 regulates 
osteoclastogenesis. First, I found that TG2, among TG family members, was 
i
selectively expressed in osteoclast precursors and pre-fusion osteoclasts (pOCs). 
I next used TG2 siRNA and TG2 knockout mice to investigate the role of TG2 
in osteoclast differentiation. I confirmed that reduction of TG2 increased 
formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated 
cells (MNCs). Western blot and real-time PCR analyses demonstrated that the 
TG2 deficiency significantly increased the expression of osteoclastogenic 
transcription factors such as c-fos and nuclear factor of activated T cell c1 
(NFATc1). Moreover, reduction of TG2 augmented the activation of MAPKs, 
ERK, JNK and p38, and NF-κB signaling pathways by RANKL. In addition, I 
found that the TG2 deficiency increased nuclear translocation of NFATc1 and 
p65. Consequently, TG2 deficiency resulted in a potent increase of sealing zone 
formation and bone resorption activity. In contrast, TG2 overexpression 
suppressed osteoclast formation and expression of osteoclastogenic genes in 
RAW264.7 cells. B lymphocyte induced maturation protein 1 (Blimp1) has 
been shown to be a positive regulator of osteoclastogenesis and to be induced 
by the activation of NF-κB signaling pathway. As TG2 was reported to suppress 
Blimp1 expression, I investigated the interrelationship between TG2 and 
Blimp1 in osteoclast differentiation. I found that reduction of TG2 increased 
Blimp1 expression in BMMs and pOCs. Furthermore, the augmentation of 
osteoclastogenesis by TG2 knockdown was attenuated by Blimp1 knockdown. 
ii
In addition, TG2 knockout mice exhibited lower bone mass compared to 
wildtype mice. Bone histomorphometry revealed higher number and surface 
area of osteoclasts in TG2 knockout mice. In conclusion, these results indicate 
that TG2 plays an inhibitory role in osteoclast differentiation and function via 
Blimp1. 
Keywords : Osteoclast differentiation, Transglutaminase 2, c-fos, NFATc1, 
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I. Introduction 
Bone is a dynamic tissue that is continuously remodeled and maintained by a 
coupled action of osteoclasts and osteoblasts (Martin and Sims, 2005; 
Mukherjee and Rotwein, 2012). Osteoclasts and osteoblasts regulate the bone 
homeostasis by balancing the activities of bone resorption and bone formation, 
respectively (Fig. 1). Thus, the imbalance in bone remodeling can lead to bone 
diseases such as osteoporosis, periodontal disease, Paget’s disease, and 
rheumatoid arthritis (Braun and Zwerina, 2011; Harada and Rodan, 2003; 
Teitelbaum, 2000; Walsh et al., 2006).  
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Figure 1. Osteoclast-osteoblast coupling. 
Osteoblastic cell produces osteoclast differentiation factor RANKL and M-CSF. 
Haematopoietic stem cells (HSCs) undergo differentiation to osteoclasts by RANKL 
stimulation. HSC-derived osteoclasts resorb bone and release growth factors and 
calcium. Osteogenic factors, growth factors and calcium induce osteoblast 
differentiation from mesenchymal stem cells (MSCs). Osteoblasts replace the resorbed 




1. Osteoclast differentiation 
 
Osteoclasts are tartrate-resistant acid phosphatase (TRAP)-positive 
multinucleated cells (MNCs) that differentiate from the 
monocytes/macrophages of hematopoietic lineage cells (Hayashi et al., 1998; 
Teitelbaum et al., 1997). Osteoclast differentiation is induced by stimulation of 
two major factors, macrophage-colony stimulating factor (M-CSF) and receptor 
activator of nuclear factor κB (NF-κB) ligand (RANKL) (Fig. 2). M-CSF is 
critical for monocyte/macrophage lineage commitment (Valledor et al., 1998). 
M-CSF binds to its receptor, c-Fms, on osteoclast precursor cells and induces 
the expression of receptor activator of NF-κB (RANK), which is the receptor on 
these cells for RANKL (Arai et al., 1999). RANKL initiates its signal 
transduction through binding to RANK and induces the differentiation and 
fusion of osteoclast precursor cells into mature osteoclasts (Boyle et al., 2003; 
Suda et al., 1999). In particular, RANKL stimulates the activation of NF-κB 
and mitogen-activated protein kinases (MAPKs), including extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 (Asagiri and 
Takayanagi, 2007; Iotsova et al., 1997; Wong et al., 1998). RANKL stimulation 
also induces c-fos expression and thus activates the activator protein-1 (AP-1) 
３ 
 
complex containing c-fos and c-jun (Wagner and Eferl, 2005). RANKL-
induced activation of NF-κB and AP-1 complex is required for the induction of 
nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), a key transcription 
factor for osteoclast differentiation (Grigoriadis et al., 1994; Khosla, 2001). 
NFATc1 is auto-amplified by binding to NFAT binding sites on its own 
promoter (Asagiri et al., 2005; Nakashima and Takayanagi, 2011). In addition 
to its essential role in early differentiation, NFATc1 is likely to be involved in 
regulating osteoclast function. TRAP is responsible for bone resorption activity 
(Takayanagi et al., 2002). v-ATPase subunit d2 (ATP6v0d2) (Lee et al., 2006) 
and dendritic cell-specific transmembrane protein (DC-STAMP) (Kukita et al., 
2004; Yagi et al., 2005) were shown to be essential for mononuclear osteoclast 
fusion. These genes are directly induced by NFATc1 during osteoclastogenesis 
(Kim et al., 2008; Reddy et al., 1995). Mature osteoclasts form a ring-shaped 
sealing zone (SZ) for contact with the bone surface (Kanehisa et al., 1990; 
Saltel et al., 2004; Tehrani et al., 2006). These active osteoclasts resorb the bone 
matrix by secreting acid and proteases, such as TRAP, cathepsin K and matrix 
metalloprotease 9 (MMP9) within the resorption pit (lacuna) for bone 
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Figure 2. Schematic representation of osteoclast differentiation. 
M-CSF and RANKL are key cytokines during osteoclast differentiation. M-CSF 
regulates proliferation, survival and cytoskeletal reorganization and induces RANK 
expression. RANKL binds to its specific membrane-bound receptor RANK and 
activates NF-κB, MAPKs, calcium signaling pathways which are crucial for the 
induction of NFATc1. NFATc1 is autoamplified by binding to an NFAT-binding site on 




2. Role of Blimp1 in osteoclast differentiation 
 
B lymphocyte induced maturation protein 1 (Blimp1) (encoded by Prdm1) is 
a zinc finger transcriptional repressor and plays crucial roles in the 
differentiation and/or function of various kinds of cells such as macrophages 
and lymphocytes (Martins and Calame, 2008). In particular, Blimp1 has been 
shown to function as a master regulator of terminal differentiation of antibody-
secreting B lymphocytes through direct repression of transcription factors 
(Shapiro-Shelef et al., 2003) and homeostasis of effector T cells (Calame et al., 
2003; Martins et al., 2006), and specification of primordial germ cells (Ohinata 
et al., 2005; Vincent et al., 2005). Blimp1 was originally identified as a silencer 
of IFN-β gene transcription (Keller and Maniatis, 1991) and has been reported 
to be regulated by various transcription factors, such as NF-κB (Johnson et al., 
2005; Morgan et al., 2009; Sen, 2006; Wang et al., 2009), AP-1 (Vasanwala et 
al., 2002; Yu et al., 2012), STAT3 (Kwon et al., 2009; Reljic et al., 2000) and 
IRF-4 (Gupta et al., 2001; Sciammas et al., 2006). Blimp1 was also reported to 
be important for osteoclast differentiation and to be induced early by NFATc1 
upon RANKL stimulation (Zhao and Ivashkiv, 2011) (Fig. 3). Blimp1 
suppresses expression of anti-osteoclastogenic genes such as interferon 
６ 
 
regulatory factor-8 (IRF-8) and v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein B (MafB), which were observed to be repressed 
during osteoclastogenesis (Nishikawa et al., 2010; Smink et al., 2009). 
Moreover, IRF-8 and MafB was reported to negatively regulate expression and 
function of NFATc1 during osteoclastogenesis (Kim et al., 2007; Wagner, 2010; 
Zhao et al., 2009). Eventually, this repression of IRF-8 and MafB by Blimp1 
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Figure 3. The mechanism of Blimp1 in osteoclast differentiation. 
RANKL stimulation recruits TRAF6 and activates NF-κB, MAPKs and co-stimulatory 
signaling pathways. Activation of these signaling pathways up-regulates NFATc1 
expression. Subsequently NFATc1 induces Blimp1 expression which suppresses 
negative regulators, IRF-8, MafB and Bcl6. Next, NFATc1 is auto-amplified and 




3.  Function of transglutaminase family 
 
Transglutaminase (TG) family consists of at least 8 distinct members (Table 
1): factor XIII A (Griffin et al., 2002), TG1 (or keratinocyte TG), TG2 (or 
tissue TG), TG3 (or epidermal TG), TG4 (or prostate TG), TG5 (or TG X), 
TG6 (or TG Y), and TG7 (or TG Z). Transglutaminase family catalyzes three 
types of Ca2+-dependent posttranslational modification reactions: 
transamidation, esterification, and hydrolysis. These reactions play important 
roles in various biological processes such as proliferation (Barone et al., 2007; 
Dardik et al., 2007), differentiation (Balajthy et al., 2006; Steinert et al., 1996; 
Sturniolo et al., 2003), cell death (Datta et al., 2007; Fesus and Szondy, 2005; 
Sarang et al., 2005; Yuan et al., 2005), inflammation (Kim et al., 2002; Quan et 
al., 2005), cell migration (Akimov and Belkin, 2001; Kang et al., 2004), and 
wound healing (Inada et al., 2000; Nahrendorf et al., 2006). TG2 acts as a 
multifunctional protein due to multiple functional domains and the functions of 
TG2 depend on the cellular localization and its regulators (Fig. 4). In addition 
to Ca2+-dependent catalytic activity, TG2 is distinguished from other family 
members by several unique characteristics such as ubiquitous expression, non-
enzymatic functions of GTPase activity, and cell-matrix interaction (Zemskov 
９ 
 
et al., 2006). Ca2+ and GTP are two important regulators, which act as switches 
between the two distinct functions, transglutaminase (Iismaa et al., 2009; 
Lorand and Graham, 2003; Steinert et al., 1999) and GTPase (Begg et al., 
2006a; Begg et al., 2006b; Di Venere et al., 2000; Iismaa et al., 2000) activities, 





Table 1.  







mass in kDa) 
Gene Prevalent function 
Factor XIII A 
Catalytic A subunit of Factor 
XIII found associated with B 
subunit in plasma as A2B2 
heterotetramer.  
Fibrin stabilizing factor 
732 (83) F13A1 Blood clotting and wound healing 
TG1 Keratinocyte Tgase 814 (90) TGM1 
Cell envelope 
formation in the 
differentiation of 
keratinocytes 
TG2 Tissue Tgase 686 (80) TGM2 














particularly in rodents 
TG5 Tgase X 719 (81) TGM5 Epidermal differentiation 
TG6 Tgase Y  TGM6 Not characterized 
TG7 Tgase Z 710 (80) TGM7 Not characterized 
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Figure 4. Biochemical activities of transglutaminase 2 
TG2 is a multifunctional protein containing multiple subcellular compartments. TG2 
has functions as transglutaminase, protein kinase, cell surface adhesion mediator, G 
protein, protein disulfide isomerase and isopeptidase. Functions of TG2 regulate 





4. Purpose of this study 
 
Several studies have reported effects of transglutaminase family members, 
especially TG2 and factor XIII A, on bone formation and metabolism 
(Nurminskaya and Kaartinen, 2006). TG2 and factor XIII A regulate the matrix 
crosslinking and extracellular matrix assembly which act as the major regulator 
of mineralization (Al-Jallad et al., 2011; Al-Jallad et al., 2006). In addition to 
regulating matrix mineralization and osteoblast differentiation, TG2 is 
expressed in hypertrophic condrocytes, and chondrocyte-derived 
transglutaminase induced the differentiation of primary osteoblasts leading to 
increased matrix calcification (Heath et al., 2001; Nurminskaya et al., 2003). 
Despite these studies, the relationship of TG2 with osteoclastogenesis has yet to 
be elucidated. To gain better knowledge in the crucial role of TG2 in vitro and 
in vivo, I examined whether TG2 is involved in regulation of osteoclastogenesis 




II. Materials and methods 
 
1. Animals 
TG2 knockout mice generated by Vincenzo De Laurenzi (De Laurenzi and 
Melino, 2001) were provided by Prof. In-Gyu Kim (Seoul National University, 
College of Medicine, Korea). All mice were fed a regular diet and water and 
maintained on a 12 hr light/night cycle at the animal facility of Seoul National 
University School of Dentistry. 5-wk-old ICR mice for isolation of primary 
bone marrow derived-macrophages (BMMs) were purchased from OrientBio, 
Korea. All animal experiments were performed with the approval of the 
Institutional Animal Care and Use Committee at Seoul National University. 
 
2. Reagents 
Recombinant RANKL and M-CSF were from Peprotech EC Ltd. (London, 
UK). Anti-TG2, anti-c-fos, anti-NFATc1, anti-α-tubulin and NF-κB inhibitor 
BAY 11-7085 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Anti-Blimp1 was purchased from Abcam (Cambridge, UK). Polyclonal 
antibodies against ERK, JNK, p38, IκB, phospho-ERK, phospho-JNK, 
phospho-p38, phospho-IκB and PARP were purchased from Cell Signaling 
１４ 
 
Technology (Cambridge, MA, USA). Monoclonal antibody against β-actin and 
horseradish peroxidase (HRP)-conjugated secondary antibodies were from 
Sigma Aldrich (St Louis, MO, USA). NFATc1 and NF-κB p65 Transcription 
Factor Assay Kits were purchased from Active Motif (Carlsbad, CA, USA). 
Cell counting kit-8 (CCK) was obtained from Dojindo (Kumamoto, Japan). NE-
PER Nuclear and Cytoplasmic extraction reagents kit was obtained from Pierce 
Biotechnology (Rockford, lL, USA). BrdU cell proliferation assay kit was 
purchased from Calbiochem (Darmstadt, Germany). TRAP staining kit and 
other reagents were purchased from Sigma Aldrich. 
 
3. Bone marrow derived-macrophages (BMMs) generation 
Bone marrow of tibiae and femurs of 5-wk-old mice were flushed with α-
MEM (Welgene, Daegu, Korea). After removing erythrocytes with hypotonic 
buffer, cells were cultured in α-MEM containing 10% FBS for 24 hr and 
adherent cells were discarded. Non-adherent bone marrow cells were 
transferred onto 100 mm non-coated Petri dishes at 5 × 106 cells per dish and 
cultured in the presence of M-CSF (30 ng/ml) for 3 days. Adherent cells at this 
stage were considered bone marrow derived-macrophages (BMMs) after the 
non-adherent cells were washed out. 
１５ 
 
4. Cell culture 
BMMs were cultured in α-MEM supplemented with 10% (v/v) heat-
inactivated FBS, 100 units/ml of penicillin and 100 μg/ml of streptomycin, and 
incubated at 37oC in 5% CO2. BMMs were plated in 60 mm dish at 5 × 105 cells 
and 48-well culture plates at 4 × 104 cells per well. RAW264.7 and 293FT cells 
were cultured in DMEM supplemented with 10% (v/v) heat-inactivated FBS, 
100 units/ml of penicillin and 100 μg/ml of streptomycin, and incubated at 37oC 
in 5% CO2. RAW264.7 cells were plated in 48-well culture plates at 1 × 104 
cells per well and 293FT cells were plated in 60 mm culture dishes at 4 × 105 
cells.  
 
5. Preparation of cytoplasmic and nuclear protein lysates 
Cytoplasmic and nuclear protein lysate were prepared from BMMs using the 
NE-PER Nuclear and Cytoplasmic extraction reagents kit (Pierce 
Biotechnology) according to the manufacturer’s instructions. In brief, cultured 
cells were washed with PBS and treated with cell lysis buffer. After 
centrifugation, the cleared supernatant was transferred to a new tube as 
cytoplasmic extract. The nuclear pellet was washed twice and lysed with 
nuclear lysis reagent. After centrifugation, the cleared supernatant was used as 
１６ 
 
the nuclear protein extract. Protein concentration was determined using a 
detergent-compatible colorimetric assay kit (Bio-Rad Laboratories, CA, USA). 
 
6. RT-PCR and quantitative real-time PCR 
Total RNA was extracted from BMMs and RAW264.7 cells at the indicated 
time points. After isolation of total RNA using TRIZOL (Invitrogen), reverse 
transcription was performed using 2 μg of total RNA and a superscript II 
reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. For 
amplification of TG family, RT-PCR was performed with a cycle of 
denaturation at 95°C for 15 sec and annealing/extension at 60°C for 60 sec for 
26 cycles. PCR products were separated in a 1.5% agarose gel and stained with 
ethidium bromide. Expression of target genes was analyzed using the HPRT 
housekeeping gene as an input control. Real-time PCR was performed with the 
ABI 7500 real-time system using KAPA SYBR FAST qPCR kit (Kapa 
Biosystems, MA, USA). The detector was programmed with the following PCR 
conditions: 40 cycles for 3 sec denaturation at 95°C and 33 sec amplification at 
60°C. All reactions were run in triplicates and were normalized using the HPRT 
gene, and values indicating the fold-change from control are shown. Relative 
differences in PCR results were evaluated by the comparative cycle threshold 
method. All primer sets for RT-PCR and real-time PCR are listed in Table 2. 
１７ 
 
7. Gene cloning and lentivirus gene transduction 
To generate TG2 overexpressed stable RAW264.7 cells, the 2061 bp cDNA 
(GenBank accession number NM_009373.3) fragment of TGM2 was obtained 
by RT-PCR of mRNA from BMMs. The PCR reaction steps included initial 
denaturation at 95°C for 5 min followed by reaction cycles of denaturation at 
95°C for 30 sec, annealing at 56°C for 30 sec, and extension at 72°C for 4 min. 
The following primers were used: TG2, 5′-
GGACTAGTGCCACCATGGCAGAGGAGCTGCTC -3′ (sense) and 5′-
TCCCCGCGGGGCCGGGCCGATGATAAC-3′ (antisense). pLenti6 lentiviral 
vector and PCR product were cleaved with SpeI and SacII restriction enzymes 
and subjected to 1% agarose gel electrophoresis. Each DNA fragment was 
purified from the gel and TG2 fragment was cloned into identical sites of 
pLenti6 vector. To generate lentiviral particles, 293FT cells were transfected 
with pLenti6-LacZ (control) or pLenti6-TG2 plasmid using polyfect 
transfection reagent. Viral supernatant was harvested after 48 hr and passed 
through 0.45 μm syringe filter. RAW264.7 cells were infected with viral 
supernatant mixed with polybrene (6 μg/ml) for 18 hr. After overnight 
incubation, infected RAW264.7 cells were selected with blasticidin (1:2000) for 
15 days. Forced expressions of each construct were determined by amounts of 
mRNA and protein expression levels. 
１８ 
 
8. Cell proliferation assay 
TG2 knockdown (BrdU assay) and knockout (CCK assay) BMMs were 
cultured for 1-3 days. After TG2 knockdown, BMMs were subjected to BrdU 
assay following the manufacturer's instruction. For CCK assay, TG2 knockout 
BMMs were incubated with 10% CCK solution in cell culture medium for 30 
min at 37°C. After incubation, optical density was measured with an ELISA 
reader at 450 nm.  
  
9. Western blot 
BMMs and RAW264.7 cells were lysed with a lysis buffer containing 120 
mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% 
NP40, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3VO4, 1 mM NaF, and protease inhibitors (Roche, Mannheim, Germany). 
The protein concentration of cell lysates was determined by Dc protein assay kit 
(Bio-Rad, Hercules, CA, USA) and equal amounts of protein were loaded onto 
10 or 12% SDS-polyacrylamide gel. After transfer onto nitrocellulose 
membranes (Amersham Pharmacia, Uppsala, Sweden) and blocking with 5% 
nonfat skim milk, primary antibodies were added and incubated for overnight at 
4°C. The immunoreactivity was detected with ECL reagents (Pierce, Rockford, 
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IL, USA) after incubation with HRP-conjugated secondary antibodies for 1 hr 
in 2% skim milk. Comparable loading was verified by reprobing the same 
membranes with anti-β-actin antibody. 
 
10. TRAP staining and osteoclast measurement 
To generate osteoclasts, BMMs and RAW 264.7 cells were plated in 48-well 
tissue culture plates at density of 4 × 104 cells/well and 1 × 104 cells/well, 
respectively. Cells were cultured in the presence or absence of RANKL (100 
ng/ml) for 3 or 4 days. The BMMs culture was supplemented with M-CSF (30 
ng/ml). The culture medium was changed at day 2. Under this condition, 
TRAP-positive mononuclear cells were detected at day 2 and TRAP-positive 
multinucleated cells (MNCs) were observed at days 3 and 4. The cells were 
fixed with 3.7% formaldehyde for 30 min at room temperature. After 
permeabilized with 0.1% Triton X-100 for 5 min, TRAP staining was 
performed in the dark for 30 min using a TRAP kit following the manufacturer's 
instructions. After staining, cells were washed with distilled water and observed 
under a light microscope. On light microscopy, osteoclasts were seen as TRAP-
positive multinucleated ( ≥ 3 nuclei) cells. The total number of TRAP-positive 
MNCs and the surface area per TRAP-positive MNCs were measured using the 
Osteomeasure software (OsteoMetrics, Inc. Decatur, GA, USA). The 
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morphological features of osteoclasts were also photographed. 
 
11. Resorption assay 
BMMs were seeded on dentine discs (Osteosite Dentine Discs, 
Immunodiagnostic Systems Inc, Boldon, United Kingdom) and stimulated with 
RANKL for 7 days. There were typically 4 dentine discs per group. Cells were 
removed with 5% sodium hypochlorite for 10 min. Discs were wiped using 
cotton swab and rinsed with distilled water. Photographs were taken, and the 
area and depth of resorption pits were measured with a Carl Zeiss LSM 5-
PASCAL laser-scanning microscope (Carl Zeiss Microimaging GmbH, 
Goettingen, Germany). Results are expressed as the resorbed area and depth per 
resorption pit.  
 
12. Confocal microscopy 
BMMs were seeded on glass cover slips in 24-well plates at a density of 7 × 
104 cells per well. Cultured cells were fixed with 3.7% formaldehyde and 
permeabilized with 0.1% triton X-100. After blocking in PBS containing 1% 
BSA, cover slips were incubated with suitable primary antibodies (1:100) of 
each experiment for overnight at 4°C. Subsequently, cells were washed and 
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incubated with suitable Alexa Fluor® 647, FITC- or Cy3-conjugated secondary 
antibodies (1:250) of each experiment for 1 hr at room temperature. For sealing 
zone formation assay, BMMs were cultured in the presence of M-CSF (30 
ng/mL) and RANKL (100 ng/ml) in α-MEM supplemented with 10% FBS. 
After 3 days in culture, mature osteoclasts were fixed and stained using 
rhodamine-phalloidin (red; actin) and DAPI (blue; nucleus). The mean intensity 
of sealing zone per osteoclast was measured using Zen 2009 software (Carl 
Zeiss). For p65 nuclear translocation assay, BMMs were serum-starved for 5 hr 
and stimulated with RANKL (500 ng/ml) for the indicated time. Stimulated 
cells were fixed and performed immunocytochemistry staining using anti-
laminB (green; nucleus) and anti-p65 (red; p65). For NFATc1 nuclear 
translocation assay, BMMs were cultured in the presence of M-CSF (30 ng/mL) 
and RANKL (100 ng/ml). After 2 days in culture, osteoclast precursors were 
fixed and stained using anti-laminB (green; nucleus), anti-NFATc1 (red; 
NFATc1) and anti-TG2 (blue; TG2). The cover slips were mounted and cell 
images were obtained using a Zeiss LSM 700 confocal microscope (Carl Zeiss 






13. Three-dimensional microcomputed tomography analysis  
Femurs of 13-week old female TG2 knockout mice and WT littermate mice 
(6 per genotype) were fixed in 4% (vol/vol) paraformaldehyde for overnight 
and analyzed by micro-computed tomography (micro-CT) using the SkyScan 
1072 system (SkyScan, Kontich, Belgium). Trabecular bone parameters were 
measured in the trabecular regions 1 mm away from 1 mm below the proximal 
edge of growth plate in the distal end of the femur. A total of 350-400 
tomographic slices were acquired and three-dimensional analyses were 
performed with CT-volume software (ver 2.1.1.0; Skyscan). 
 
14. Histomorphometrical analysis 
Bone histomorphometric analyses were performed on paraffin-embedded 
sections. In brief, femurs were fixed in 4% paraformaldehyde, decalcified in 12% 
EDTA for 4 wk, and embedded in paraffin. The paraffin blocks were serially 
sectioned at a thickness of 6 μm and stained with TRAP/ hematoxylin or 
hematoxylin/eosin according to standard procedures. Trabecular bone 
parameters were analyzed using the Osteomeasure software and morphological 





15. Statistical analysis  
All values represent mean ± SD. Statistical significance was determined 
using the Student t test (two-tailed distribution with two-sample equal variance) 
for in vitro and in vivo studies. For judgment, P values less than 0.05 was 





Primers for RT-PCR and quantitative real-time PCR experiments 
 
Gene  Sequence Size (bp) 
GenBank 
accession # 
(TG family)  5’-                          -3’   
mouse TG1 
Sense CATTGGCACACTCATTGTCA 
143 NM_001161715 Antisense ACACATTAGGTTTGCTGCCA 















mouse TG7 Sense CCAATTTCCATTCTGCACAC 136 NM_001160424 
Antisense ATCATCCAGCACTCATTCCA 
mouse Factor XIII A 
Sense TGAGCTCCAAACTCACCAAG 
145 NM_028784 Antisense CGGTACATGCCATCACTGTT 
(OC makers)  5’-                          -3’   
mouse c-fos 
Sense ACTTCTTGTTTCCGGC 
233 NM_010234 Antisense AGCTTCAGGGTAGGTG 













141 NM_007548 Antisense GCTGATGTCGAACCTCTCAA 











1. TG2, among TG family members, is selectively expressed 
in BMMs and pOCs. 
 
To investigate the expression pattern of TG family members in BMMs and 
osteoclast precursors, BMMs were cultured in the presence or absence of 
RANKL for 2 days. Among the TG family members, TG2 was dominantly 
expressed in both BMMs and pOCs treated with RANKL for 2 days. Factor 
XIII A was weakly detected. In contrast to TG2 and factor XIII A, other TG 






Figure 5. TG2 is selectively expressed in BMMs and pOCs. 
BMMs were treated with M-CSF (30 ng/ml) with or without RANKL (100 ng/ml) for 2 
days. mRNA expression for TG1-TG7 and factor XIII A was analyzed by RT-PCR. The 





2. TG2 knockdown increases osteoclast differentiation 
induced by RANKL.  
 
Next, the effect of TG2 in the osteoclast differentiation was examined using 
the siRNA knockdown system. To do this, control or TG2 siRNA was 
transfected to BMMs. These cells were then treated with RANKL, and 
examined for knockdown efficiency. Quantitative real-time PCR analyses 
showed that TG2 mRNA levels were reduced more than 50% in the TG2 siRNA 
transfected BMMs and this extent of reduction was sustained (Fig. 6A). 
Western blotting experiments also showed suppression of TG2 by siRNA at the 
protein levels (Fig. 6B). 
To confirm the effect of TG2 knockdown on osteoclast formation, I examined 
that BMMs were transfected with TG2 siRNA and incubated with RANKL for 
3 days. When TG2 was knockdowned during osteoclastogenesis, the generation 
of TRAP-positive MNCs was enhanced (Fig. 7A). Moreover, the number of the 
TRAP-positive MNCs was also increased by TG2 knockdown (Fig. 7B). c-fos 
and NFATc1 are master transcriptional factors in RANKL-induced osteoclast 
differentiation. I therefore investigated whether TG2 knockdown affects the 
expression of c-fos and NFATc1. These results demonstrate that expression 
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levels of c-fos and NFATc1 were significantly increased in TG2 knockdowned 
cells (Fig. 7C, D). These data indicate that TG2 knockdown enhances RANKL-











Figure 6. TG2 siRNA efficiently decreased TG2 mRNA and protein levels. 
BMMs were transfected with control or TG2 siRNA for 18 hr and stimulated with 
RANKL for the indicated times. (A) mRNA level of TG2 was measured using real-
time PCR. Gene expression was normalized using the HPRT housekeeping gene, and 
values indicating the fold-change from control are shown. (B) Whole cell lysates were 
subjected Western blot analysis with anti-TG2. Real-time PCR data shown are 
representative of three independent experiments performed in triplicate. **, p < 0.005 
versus stimulation with RANKL alone. All data are expressed as mean ± SD. 
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Figure 7. TG2 knockdown increased osteoclast formation by RANKL. 
(A) TG2 knockdowned BMMs were stimulated with RANKL for 3 days, and TRAP 
staining was performed. (B) TRAP-positive MNCs (≥3 nuclei) were counted as 
osteoclasts. Scale bar, 200 μm. (C) mRNA levels of c-fos and NFATc1 were measured 
using real-time PCR. (D) Whole cell lysates were subjected Western blot analysis with 
c-fos and NFATc1 antibodies. The data shown are representative of three independent 
experiments performed in triplicate. **, p < 0.005 versus stimulation with RANKL 





3. TG2 knockdown promotes bone resorption activity. 
 
To explore further the influence of TG2 knockdown on osteoclast activity, the 
expression levels of genes encoding proteins related to osteoclast fusion and 
bone resorption activity were examined using real-time PCR. The expression of 
osteoclast activity related genes (TRAP, DC-STAMP and ATP6v0d2) was 
increased in TG2 knockdowned cells (Fig. 8). Next, the effect of TG2 
knockdown on the resorption activity of osteoclasts was investigated. 
Consistent with the observations of the increase of c-fos and NFATc1, and the 
number of TRAP-positive MNCs, TG2 knockdown caused an increase in the 
resorbed area and depth per osteoclast (Fig. 9A, B).These data indicate that 
regulation of TG2 expression in osteoclasts affects a significant mechanism to 






Figure 8. TG2 knockdown increased the expression of osteoclast activity 
related genes. 
mRNA was isolated from the control siRNA or TG2 siRNA transfected BMMs at the 
indicated times. Expression of TRAP, DC-STAMP and ATP6v0d2 were analyzed by 
real-time PCR.  *, p < 0.05; **, p < 0.005 versus stimulation with RANKL alone. All 








Figure 9. TG2 knockdown stimulated the osteoclast resorption activity. 
(A) BMMs were transfected with control or TG2 siRNA and dentine resorption assay 
was performed. Black areas indicate resorbed lacunae on dentin slice. Scale bar, 100 
μm. (B) Resorbed area and depth per osteoclast were calculated from randomly 
selected four images. *, p < 0.05; **, p < 0.005 versus stimulation with RANKL alone. 
All data are expressed as mean ± SD. 
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4. TG2 knockdown activates the RANKL-induced MAPKs 
and NF-κB signaling pathways. 
 
To determine the intracellular mechanism of TG2 action, I investigated the 
activation of MAPKs involved in the RANKL signaling pathway. BMMs were 
stimulated with RANKL and the activation state of ERK, JNK and p38 
activation was determined by Western blot analysis using phosphorylated form 
detectable antibodies. RANKL induced the activation of all three MAPKs at 5 
and 15 min. In TG2 knockdown BMMs, the phosphorylation of ERK, JNK and 
p38 was greater than the control BMMs, whereas total levels of MAPKs were 
not changed (Fig. 10A). I next examined the effect of TG2 on the growth of 
BMMs (Fig. 10B). TG2 had little effect on the growth of BMMs, although TG2 
knockdown slightly increased BrdU incorporation on day 1.  
NF-κB signaling pathway is one of the crucial signaling pathways in 
RANKL-induced osteoclast differentiation. It has been well investigated that 
phosphorylation of IκB and transcriptional activity of p65 were enhanced by 
RANKL stimulation in osteoclast precursors (Iotsova et al., 1997; Wong et al., 
1998). To investigate whether TG2 knockdown regulates NF-κB signaling 
pathway, we examined the phosphorylation level of IκB in osteoclast precursors. 
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RANKL stimulation induced phosphorylation of IκB within 5 min, and the 
level of RANKL-induced IκB phosphorylation was further enhanced by TG2 
knockdown at 5 and 30 min (Fig. 11A). I further examined whether p65 
transcriptional activity was increased in TG2 knockdown BMMs. The p65 
transcriptional activity assay showed that the TG2 knockdown increased the 
activity of p65 at 15 min (Fig. 11B). These results suggest that TG2 knockdown 
increased the activation of the MAPKs and NF-κB signaling pathways by 
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Figure 10. TG2 knockdown enhanced the activation of MAPKs signaling 
pathway by RANKL. 
(A) At 48 hr after siRNA transfection, BMMs were serum starved for 5 hr and 
stimulated with RANKL (500 ng/ml) for the indicated times. Whole cell lysates were 
subjected to Western blot analysis with MAPKs pathway relevant antibodies. (B) 
BMMs were cultured for the indicated time and BrdU assay was performed. *, p < 0.05 










Figure 11. TG2 knockdown increased the activation of NF-κB signaling 
pathway by RANKL. 
BMMs were transfected with control or TG2 siRNA. (A) At 48 hr after transfection, 
BMMs were serum starved for 5 hr and stimulated with RANKL (500 ng/ml) for the 
indicated times. Whole cell lysates were subjected to Western blot analysis with 
phospho-IκB and IκB antibodies. (B) Nuclear fraction was harvested from cultured 
cells and subjected to p65 Transcription Factor Assay. *, p < 0.05 versus stimulation 
with RANKL alone. All data are expressed as mean ± SD. 
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5. TG2 knockdown up-regulates Blimp1 expression by 
enhancing the NF-κB signaling pathway. 
 
To explore the target of TG2, I examined the mRNA and protein expression 
levels of Blimp1 in TG2 knockdown cells for the indicated times. The mRNA 
expression level of Blimp1 by TG2 knockdown was much higher than that by 
control siRNA transfection (Fig. 12A). I also observed that TG2 knockdown 
enhanced the RANKL-induction of Blimp1 proteins in BMMs and pOCs (Fig. 
12B). I further examined whether the increase of Blimp1 by TG2 knockdown 
was due to activation of NF-κB pathway. Inhibition of NF-κB pathway with 
BAY 11-7085 attenuated the induction of Blimp1 (Fig. 13A, B). BAY 11-7085 
also significantly down-regulated the stimulation of RANKL-dependent 
induction of NFATc1 by TG2 knockdown (Fig. 13B). Interestingly, the 
expression level of c-fos was not affected by BAY 11-7085 treatment. These 
results suggest that TG2 regulates Blimp1 expression during RANKL-










Figure 12. TG2 knockdown increased Blimp1 expression. 
BMMs were transfected with control or TG2 siRNA. (A, B) siRNA transfected BMMs 
were cultured for the indicated times in the presence of M-CSF and RANKL. 
Expression of TG2 and Blimp1 was examined by real-time PCR (A) and Western blot 
(B) analyses. *, p < 0.05; **,p < 0.005 versus stimulation with RANKL alone. All data 
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Figure 13. TG2 knockdown increased Blimp1 induction by RANKL 
through activation of NF-κB signaling pathway. 
BMMs were transfected with control or TG2 siRNA. (A, B) TG2 siRNA transfected 
BMMs were cultured with or without BAY 11-7085 (5 μM) for 2 days. (A) Western 
blot analysis was performed to assess the expression of the indicated proteins. (B) PCR 
was performed to analyze the mRNA expression levels of TG2, Blimp1, c-fos and 




6. Blimp1 knockdown attenuates the up-regulation of 
NFATc1 by TG2 suppression. 
 
To further clarify the role of the TG2/Blimp1 axis in RANKL-induced 
osteoclastogenesis, I investigated the alteration of osteoclast formation by TG2 
and/or Blimp1 knockdown. As previously shown, TG2 knockdown significantly 
enhanced the formation of the TRAP-positive MNCs by RANKL. This 
enhancement of osteoclast formation by TG2 knockdown was significantly 
reduced by Blimp1 knockdown (Fig. 14A, B). Not only the number of TRAP-
positive MNCs but also the size of TRAP-positive MNCs were decreased by 
knockdown of TG2 and Blimp1 (Fig. 14B, C).  
I further examined whether knockdown of TG2 and Blimp1 affects the 
expression of c-fos and NFATc1. Osteoclast precursors transfected with TG2 
and Blimp1 siRNA were stimulated by RANKL treatment for 2 days and 
subjected to Western blot and real-time PCR to determine expression levels of 
both protein and mRNA (Fig. 15A, B). Western blot and real-time PCR 
analyses revealed that TG2 knockdown increased expression level of NFATc1. 
Interestingly, a decrease of Blimp1 was associated with a significant reduction 
in the up-regulation of NFATc1 by TG2 knockdown. In contrast, expression 
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level of c-fos was only slightly affected by Blimp1 knockdown (Fig. 15A, B). 
These results indicate that Blimp1 knockdown was able to down-regulate 
protein and mRNA induction of NFATc1 by TG2 knockdown.  
Next, I investigated the effects of TG2 knockdown on change in intranuclear 
level of NFATc1. Analyses of NFATc1 levels in cytoplasmic and nuclear 
fractions revealed an increase of expression and nuclear translocation of 
NFATc1 by TG2 knockdown. Moreover, TG2 knockdown increased total 
Blimp1 protein level compare with control cells in nuclear fractions (Fig. 16A). 
Similar results were obtained in NFATc1 transcription factor assay. 
Transcriptional activity of NFATc1 was increased by TG2 knockdown at day 2 
after RANKL treatment (Fig. 16B). Thus, these data verify that TG2 
knockdown up-regulates NFATc1 expression and transcriptional activity via 
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Figure 14. Blimp1 knockdown attenuated the induction of osteoclast 
formation by TG2 knockdown. 
BMMs were transfected TG2 and/or Blimp1 siRNA. (A) TG2 and Blimp1 
knockdowned BMMs were cultured for 3 days with M-CSF and RANKL. Cultured 
cells were fixed and stained for TRAP. (B) Number of TRAP-positive MNCs was 
counted and surface per osteoclast was measured. The data represent means of at least 
three independent experiments performed in triplicate. *, p < 0.05; **, p < 0.005. All 











Figure 15. Blimp1 knockdown attenuated the up-regulation of NFATc1 by 
TG2 knockdown. 
BMMs were transfected with TG2 and/or Blimp1 siRNA. (A, B) After TG2 and 
Blimp1 knockdown, BMMs were analyzed by Western blot (A) and real-time PCR (B) 
at day 2 after RANKL treatment. The data represent means of at least three 
independent experiments performed in triplicate. p < 0.005. All data are expressed as 
mean ± SD.  
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Figure 16. TG2 knockdown increased the nuclear translocation and 
transcriptional activity of NFATc1. 
BMMs were transfected TG2 and/or Blimp1 siRNA. (A) Cytoplasmic and nuclear 
fractions were obtained from cells cultured for 2 days using fractionation kit and 
subjected to Western blot analysis for detection of NFATc1 and Blimp1. Antibodies for 
α-tubulin and PARP (full length) were used for the normalization of cytoplasmic and 
nuclear extracts, respectively. (B) NFATc1 transcriptional activity in nuclear extract 
was quantified by NFATc1 transcription factor assay. The data represent means of at 
least three independent experiments performed in triplicate. **, p < 0.005. All data are 






7. TG2 overexpression suppresses RANKL-induced 
osteoclast differentiation in RAW264.7 cells. 
 
To confirm that TG2 has a negative role in osteoclast differentiation, I 
examined that TG2-overexpressing lentivirus was transduced into RAW264.7 
cells and selected using the lentiviral-based system. I analyzed the expression 
level of TG2 in control and TG2-overexpressing stable RAW264.7 cells. 
Expression level of TG2 was significantly increased in TG2-overexpressing 
stable RAW264.7 cells (Fig. 17A, B). And I performed experiments using stable 
RAW264.7 cells as a gain-of-function approach. TG2 overexpression 
significantly suppressed RANKL-induced osteoclast formation (Fig. 17C). TG2 
overexpression also reduced the number of TRAP-positive MNCs and the 
surface area per osteoclast (Fig. 17D). More importantly, Real-time PCR 
analysis showed that TG2 overexpression potently reduced mRNA levels of c-
fos, NFATc1 and Blimp1 in differentiation condition (Fig. 18A). In addition, 
TG2 overexpression significantly decreased protein expression of c-fos, 
NFATc1 and Blimp1 (Fig. 18B). These results support the notion that TG2 plays 
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Figure 17. TG2 inhibited the expression of c-fos, NFATc1 and Blimp1 in 
RAW264.7 cells. 
(A) TG2 mRNA level was measured using real-time PCR. (B) Whole cell lysates were 
subjected to Western blot analysis with V5 antibody. Anti-V5 antibody was used to 
detect overexpressed TG2-V5. (C) TG2-overexpressing stable RAW264.7 cells were 
stimulated with RANKL for 4 days, and TRAP staining was performed. Red arrow: 
MNCs. Blue arrowhead: mononucleated cells. (D) TRAP-positive MNCs were counted 
and surface area per osteoclast was measured. The data shown are representative of 
three independent experiments performed in triplicate. **, p < 0.005 versus control 








Figure 18. TG2 inhibited osteoclast formation in RAW264.7 cells. 
(A) mRNA levels were measured using real-time PCR and were normalized relative to 
the expression of HPRT. (B) Whole cell lysates were subjected to Western blot analysis 
with indicated antibodies. The data shown are representative of three independent 
experiments performed in triplicate. *, p < 0.05; **, p < 0.005 versus control stable 
RAW264.7 cells. All data are expressed as mean ± SD.  
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8. TG2 knockout mice exhibits decreased bone mass. 
 
To verify the role of TG2 in vivo, bone morphologic parameters in trabecular 
of the distal femur were analyzed by micro-CT. First, I examined whether TG2 
deficiency was able to reduce bone mass in 13wk-old female mice. Three-
dimensional micro-CT images of trabecular bone of femurs revealed that the 
trabecular structure was significantly lower in TG2 knockout mice compared to 
the wildtype mice (Fig. 19A). Similarly, I analyzed the bone phenotype of TG2 
knockout mice using micro-CT. An alteration of the trabecular architecture was 
found in TG2 knockout mice (Fig. 19B). Accordingly, the micro-CT analysis of 
distal regions of femur showed significantly lower trabecular bone volume per 
tissue volume (BV/TV) in TG2 knockout mice (Fig. 19C). Further structural 
analysis indicated that trabecular thickness (Tb.Th) and trabecular number 
(Tb.N) were also decreased in TG2 knockout mice (Fig. 19C). Conversely, TG2 
deficiency significantly increased the levels of trabecular separation (Tb.sp) 
(Fig. 19C). To address whether decreased bone mass in TG2 knockout mice 
was related to increased osteoclastogenesis, I analyzed the histological bone 
sections that were stained for TRAP and with hematoxylin and eosin (Fig. 20A). 
Consistent with TG2 knockdown results, TG2 deficiency increased the number 
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of osteoclasts per bone perimeter (N.Oc/B.Pm) (Fig. 20B). Furthermore, TG2 
deficiency also enhanced the levels of osteoclast surface per bone surface 
(Oc.S/BS) and eroded surface per bone surface (ES/BS). Although TG2 
deficiency slightly decreased the number of osteoblasts per bone perimeter 
(N.Ob/B.Pm), the difference was not statistically significant (Fig. 20B). These 
observations indicate that TG2 affects the generation of osteoclasts but not 










Figure 19. TG2 deficiency decreased trabecular bone and bone parameters.  
(A) Three-dimensional micro-CT images of distal femurs of 13-wk old WT and TG2 
knockout mice (n = 6 for each group) were reconstructed with Skyscan CTvol software. 
(B) The sagittal and transaxial images were shown with DataViewer software. (C) The 
trabecular Bone volume per tissue volume (BV/TV), trabecular thickness (Tb.Th), 
trabecular number (Tb.N), and trabecular separation (Tb.Sp) in distal femurs were 
quantified by micro-CT analysis with Skyscan CTAn software. *, P < 0.05; **, p < 








Figure 20. TG2 deficiency increased osteoclast differentiation in vivo.  
(A) Tissue sections of the distal femur in WT and TG2 knockout mice were stained for 
TRAP (upper panel). Representative sections of femur, stained with hematoxylin/eosin 
(H&E), are shown (lower panel). Scale bar, 100 μm. (B) The number of osteoclasts per 
bone perimeter (N.Oc/B.Pm), osteoclast surface per bone surface (Oc.S/BS), eroded 
surface per bone surface (ES/BS), and number of osteoblasts per bone perimeter 
(N.Ob/B.Pm) were quantified (n = 6). *, P < 0.05 versus WT mice. NS, no significant 




9. TG2 knockout increases osteoclast differentiation and 
expression of c-fos, NFATc1 and Blimp1. 
 
Because histomorphometric analyses indicated that TG2 deficiency increased 
the number and surface of osteoclasts in vivo, I addressed whether TG2 
regulates osteoclast differentiation in vitro by using TG2 knockout BMMs. To 
examine this point, BMMs were prepared from WT and TG2 knockout mice. 
These cells were subjected to in vitro osteoclastogenesis by stimulation with 
RANKL. TG2 deficiency significantly increased number of TRAP-positive 
MNCs and surface area per osteoclast (Fig. 21A, B). I also found that c-fos, 
NFATc1 and Blimp1 were significantly increased in TG2 knockout cells (Fig. 
22A, B). To address how TG2 regulates osteoclast differentiation, I examined 
the intracellular localization of NFATc1 in the osteoclast precursors and pOCs. 
In osteoclast precursors, NFATc1 was localized within the cytoplasmic region 
before RANKL stimulation. After treatment with RANKL for 2 days, nuclear 
translocation of NFATc1 was increased in TG2 knockout pOCs (Fig. 23A, B; 
Lamin B, green; NFATc1, red; TG2, blue; several mononuclear cells are shown). 
These observations reveal that NFATc1 was translocalized to the nucleus by 
RANKL stimulation and it was increased by TG2 deficiency. Because of the 
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observed effect of TG2 deficiency, I further investigated its importance for 
sealing zone (SZ) formation, given the critical importance of this actin structure 
in the bone resorption process. The SZ size per osteoclast and the number of 
actin ring were significant increased the in TG2 knockout osteoclasts compared 
to control osteoclasts (Fig. 24A, B). These observations indicate that TG2 








Figure 21. TG2 deficiency enhanced osteoclast formation. 
BMMs were obtained from WT and TG2 knockout mice. (A) After treatment with 
RANKL for 3 days, cells were fixed and stained for TRAP. (B) Number of TRAP-
positive MNCs was counted and surface area per osteoclast was measured. The data 
shown are representative of three independent experiments performed in triplicate. *, P 
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Figure 22. TG2 knockout increased expression of c-fos, NFATc1 and 
Blimp1. 
BMMs were obtained from WT and TG2 knockout mice. (A) Whole cell lysates were 
analyzed by Western blot analysis using indicated antibodies. (B) mRNA expression 
levels of TG2, c-fos, NFATc1 and Blimp1 were determined by real-time PCR and 
normalized with the level of HPRT. The data shown are representative of three 
independent experiments performed in triplicate. *, P < 0.05; **, p < 0.005 versus WT 
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Figure 23. TG2 deficiency induced the nuclear translocation of NFATc1.  
BMMs were obtained from WT and TG2 knockout mice. (A) Images of osteoclast 
precursor cells before treatment with RANKL and cells after treatment with RANKL 
for 2 days are shown. Cells stained for Lamin B (green), NFATc1 (red) and TG2 (blue) 
were examined by fluorescence microscopy. Anti-LaminB stained nuclear envelope. (B) 
Cells with nuclear NFATc1 were counted. The data shown are representative of three 
independent experiments performed in triplicate. *, P < 0.05 versus WT BMMs. All 
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Figure 24. TG2 deficiency enhanced sealing zone formation. 
BMMs were obtained from WT and TG2 knockout mice. (A) BMMs were cultured 
with M-CSF and RANKL for 3 days. Cells were stained with rhodamine-phalloidin (F-
actin) and DAPI (nucleus). (B) Sealing zone (SZ) area per osteoclast and number of 
actin ring were measured. The data shown are representative of three independent 
experiments performed in triplicate. **, p < 0.005 versus WT BMMs. All data are 




10. TG2 deficiency increases the activation of MAPKs and NF-
κB signaling pathways. 
 
To further validate the target signaling pathways affected by TG2 deficiency, 
I evaluated the activation of MAPKs and NF-κB signaling pathways using the 
WT and TG2 knockout BMMs. The RANKL-induced phosphorylation of ERK, 
p38, JNK was augmented in the TG2 knockout BMMs (Fig. 25A). TG2 
deficiency had little influence on the total levels of ERK, p38 and JNK. 
Furthermore, TG2 deficiency did not affect cell proliferation (Fig. 25B). 
Because TG2 deficiency enhances the activation of ERK, p38 and JNK, I 
examined effects of MAPK inhibitors on the expression of c-fos and NFATc1 in 
TG2 knockout BMMs. Treatment of BMMs with MEK inhibitor (U0126) and 
p38 MAPK inhibitor (SB203580) strongly blocked RANKL-induced c-fos, 
NFATc1 expression (Fig. 26A, B). In case of JNK signaling, Treatment of 
BMMs with JNK inhibitor (SP600125) suppressed RANKL-induced phospho-
c-Jun and NFATc1 expression, and did not affect c-fos expression level by 
RANKL (Fig. 26C). These results demonstrate that TG2 regulates osteoclast 
differentiation through ERK, p38 and JNK signaling pathways. The RANKL-
induced IκB phosphorylation was evidently increased at 5 min and the level of 
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unphosphorylated IκB was further decreased at 30 min by TG2 deficiency (Fig. 
27A). When I examined the nuclear translocalization of p65 by RANKL 
stimulation, TG2 deficiency strongly increased distribution of p65 in the 
nucleus region of osteoclasts. Quantitative analysis showed that TG2 deficiency 
increased p65 nuclear translocation in the TG2 knockout BMMs at 15 and 30 
min (Fig. 27B). I also confirmed that TG2 deficiency increased p65 nuclear 
translocation by immunostaining (Fig 28A). RANKL-treated cells showed 
intense nuclear accumulation of p65 in TG2 knockout BMMs (Fig. 28B). These 
data indicate that the TG2 deficiency increased the activation of NF-κB 
signaling pathway by RANKL. Taken together, MAPKs and NF-κB signaling 
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Figure 25. TG2 deficiency increased the activation of MAPKs signaling 
pathway. 
(A) WT and TG2 knockout BMMs were serum-starved for 5 hr and stimulated with 
RANKL (500 ng/ml) for the indicated times. Whole cell lysates were analyzed by 
Western blot analysis using MAPKs antibodies. (B) BMMs were cultured at the 
indicated time and CCK assay was performed. The data shown are representative of 









Figure 26. Inhibition of MAPKs attenuated the increase of c-fos, p-c-jun 
and NFATc1 by TG2 deficiency. 
WT and TG2 knockout BMMs were cultured with RANKL for 2 days in the presence 
of various inhibitors: vehicle (DMSO), U0126 (5 μM), SB203580 (5 μM) or SP600125 
(10 μM). Western blot analysis was performed for the expression of indicated proteins. 











Figure 27. TG2 deficiency enhanced the activation of NF-κB signaling 
pathway by RANKL. 
(A) WT and TG2 knockout BMMs were serum-starved for 5 hr and stimulated with 
RANKL (500 ng/ml) for the indicated times. Whole cell lysates were analyzed by 
Western blot analysis using phospho-IκB and IκB antibodies. (B) WT and TG2 
knockout BMMs were fractionated and subjected to Western blot analysis with specific 
antibodies as indicated. Antibodies for α-tubulin and PARP (full length) were used for 
the normalization of cytoplasmic and nuclear extracts, respectively. Numbers represent 
densitometrically determined ratios of p65 relative to PARP using ImageJ software 
(National Institutes of Health, Bethesda, MD). The data shown are representative of 
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Figure 28. TG2 deficiency increased the nuclear translocation of p65. 
BMMs were obtained from WT and TG2 knockout mice. (A) WT and TG2 knockout 
BMMs were serum-starved for 5 hr and stimulated with or without RANKL (500 ng/ml) 
for 15 min. Cells stained for Lamin B (green) and p65 (red) were examined by 
fluorescence microscopy. Anti-LaminB stained nuclear envelope. (B) Cells with 
nuclear translocated p65 were counted. The data shown are representative of three 
independent experiments performed in triplicate. *, P < 0.05 versus WT BMMs. All 





Osteoclasts are derived from the hematopoietic lineage cell and activated to 
become mature bone-resorbing cells through the expression of transcription 
factors and functional proteins. Previous studies have demonstrated that 
transglutaminase activity is critical for regulating the cell adhesion, matrix 
secretion, deposition and differentiation of osteoblasts, and that inhibition of 
TG activity blocked these functions. However, TG2 has not yet been examined 
in osteoclast differentiation. In this study, I observed that TG2 was involved in 
osteoclastogenesis in vitro and in vivo. The important role of TG2 was revealed 
using the loss- and gain-of function approaches. First of all, I found that TG2 
was selectively expressed in BMMs and pOCs compared to other TG family 
members. TG2 knockdown significantly increased the RANKL-induced 
osteoclast formation. It could elevate the expression of RANKL-induced c-fos 
and NFATc1. I also observed that expression of osteoclast fusion and resorption 
related genes, such as TRAP, DC-STAMP and Atp6v0d2 was enhanced by TG2 
deficiency. Consequently, TG2 silencing resulted in an enhancement of bone 
resorption activity. TG2 could enhance the activation of NF-κB and MAPKs 
signaling pathways which have been reported to be involved in osteoclast 
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differentiation and action by RANKL. Furthermore, the inhibitory effect of 
TG2 on osteoclast differentiation was confirmed by TG2-overexpressing stable 
RAW264.7 cells. TG2 overexpression down-regulated the osteoclast formation 
and expression level of c-fos and NFATc1. These results provide the evidence 
for that TG2 acts as a negative regulator of osteoclast differentiation and 
activity.  
The underlying molecular signaling mechanism responsible for TG2 
mediated suppression of osteoclastogenesis was explored. One candidate is 
Blimp1, which is a master regulator in hematopoietic lineage cell development, 
maturation of B lymphocyte, and dendritic cell homeostatic development and 
function (Chan et al., 2009; Sciammas and Davis, 2004; Turner et al., 1994). 
Previous studies showed that Blimp1 expression was increased in B cells and T 
cells from TG2 knockout mice, indicating a potential relationship between 
Blimp1 and TG2 (Kim et al., 2012). Blimp1 expression was increased by 
activation of NF-κB signaling pathway (Sen, 2006; Wang et al., 2009). 
Although Blimp1 enhances NFATc1 expression by suppression of negative 
regulators in osteoclast differentiation (Zhao and Ivashkiv, 2011), it is largely 
unclear how Blimp1 regulates osteoclast differentiation. My data confirmed 
results of the previous studies that RANKL treatment significantly induced the 
expression of Blimp1 mRNA and protein, and TG2 deficiency more elevated 
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Blimp1 expression in BMMs and pOCs. NF-κB inhibitor, BAY 11-7085, 
treatment inhibited expression of Blimp1. Down-regulation of Blimp1 by 
siRNA or NF-κB inhibitor attenuated the increase of mRNA and protein levels 
of NFATc1 by TG2 knockdown. I also found that Blimp1 knockdown inhibited 
the increase of osteoclast formation by TG2 knockdown. Moreover, RANKL-
induced nuclear translocation of NFATc1 and Blimp1 was more increased by 
TG2 knockdown. As a result, I suggest that transcriptional activity of NFATc1 
was increased in TG2 knockdown cells. These data indicated that activation of 
NF-κB signaling pathway by TG2 knockdown increased Blimp1 expression. 
And Blimp1 directly enhanced expression and transcriptional activity of 
NFATc1.  
The in vivo significance of TG2 was investigated by comparing bone 
phenotypes between TG2 knockout and wildtype mice. TG2 knockout mice 
showed lower bone mass than wildtype mice. TG2 deficiency increased 
osteoclast number and surface area, as well as eroded surface in femur sections. 
In contrast to osteoclasts, TG2 deficiency did not significantly affect osteoblast 
number in vivo. Therefore, increased bone loss in TG2 knockout mice was due 
to the increase of osteoclast number and bone resorption but was not dependent 
on regulation of osteoblast number or bone formation. Similarly, in vitro 
experiments showed that BMMs obtained from TG2 knockout mice had 
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increased formation of TRAP-positive MNCs and expression of c-fos, NFATc1 
and Blimp1. Importantly, the nuclear translocation of NFATc1 and p65 was 
increased in TG2 knockout BMMs by RANKL stimulation.  
The MAPKs (ERK, JNK and p38) have been reported to be activated by 
RANKL stimulation, resulting in the activation of activating protein 1 (AP-1) 
complex. AP-1 complex containing c-fos and c-jun is required for the induction 
of NFATc1. The c-fos and c-jun were induced by ERK and p38 (Ang et al., 
2011; Huang et al., 2006; Wagner and Matsuo, 2003), and JNK (Ikeda et al., 
2004) signaling pathways for osteoclastogenesis, respectively. In this study, I 
evaluated the effects of TG2 on the activation of three MAPKs and found that 
TG2 deficiency promoted the phosphorylation of MAPKs. Moreover, treatment 
of each MAPK inhibitor attenuated the increase of c-fos, phospho-c-Jun and 
NFATc1 in TG2 knockout BMMs. These results demonstrate that TG2 
deficiency contributes to the osteoclastogenic effect partly through promoting 
phosphorylation of MAPKs in RANKL-stimulated BMMs. Figure 29 depicts a 
proposed mechanism by which TG2 regulates osteoclast differentiation. Briefly, 
TG2 down-regulation increases activation of NF-κB and MAPKs signaling 
pathways which lead to the induction of Blimp1, and c-fos and c-jun, 
respectively. Sequentially, expression and nuclear translocation of NFATc1, 
Which is a master transcription factor for osteoclastogenesis, are increased. As 
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a result, osteoclastogenesis and osteoclast activity are enhanced. 
In conclusion, this study provides evidence for inhibitory effects of TG2 on 
osteoclast differentiation and function, and suggests that TG2 is a potential 
therapeutic target for the treatment of bone destructive diseases such as 







Figure 29. Schematic illustration of a proposed mechanism by which TG2 
regulates osteoclastogenesis.  
Reduction of TG2 enhances the activation of NF-κB and MAPKs signaling pathways, 
which increase the expression levels of Blimp1, and c-fos and c-jun, respectively. 
Blimp1 together with c-fos and c-jun augments expression and nuclear translocation of 
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RANKL에 의해 유도되는 파골세포 분화과정에서 
Transglutaminase 2의 역할 
 
서울대학교 대학원 세포및발생생물학 전공 
(지도교수 : 김 홍 희) 
김 우 신 
Transglutaminase 2 (TG2)은 transglutaminase, protein kinase, cell 
surface adhesion mediator, G protein, protein disulfide isomerase, 
isopeptidase 와 같은 다양한 기능을 가진 단백질이다. 골 대사 연구분야에
서 fibronectin 과 type I collagen matrix deposition에 중요하다고 알려져 
있지만 TG2 기능 중 파골세포 형성 (osteoclastogenesis)에 관한 연구는 
아직 명확히 이루어지지 않은 상태이다. 따라서 본 연구를 통해 TG2가 파
골세포 형성을 조절하는지 여부를 밝히고자 하였다. 우선 TG family 중 
TG2가 파골 전구세포와 파골세포에서 가장 많이 발현되는 것을 발견하였
다. 또한 TG2 siRNA와 TG2 knockout 마우스를 이용하여 파골세포 분화
에서 TG2의 역할이 무엇인지 연구하였다. TG2 발현이 억제되었을 때 파골
세포 분화에 중요한 전사인자인 c-fos와 NFATc1의 발현이 증가되는 것
을 확인하였고 파골세포에 중요한 MAPKs와 NF-κB 신호전달을 확인한 
결과 TG2가 결핍되어있을 때 더 증가되는 것을 확인하였다. 또한 파골세포 
분화에 중요한 전사인자 중 NFATc1과 p65가 TG2의 발현이 억제되었을 
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때 핵으로 더 많이 이동된 것을 관찰할 수 있었다. 반대로 TG2의 발현이 
증가되었을 때는 c-fos와 NFATc1의 발현과 파골세포 형성이 억제되는 
것을 확인하였다. Blimp1은 파골세포 분화를 증가시키는 기능을 가지고 있
고 NF-κB 신호전달을 통해 발현이 증가된다는 것으로 보고되어 있다. 또
한 TG2는 Blimp1의 발현을 억제한다고 알려져 있어 파골세포 분화에서 
TG2와 Blimp1의 연관성을 연구하였다. TG2의 발현이 억제되었을 때 
Blimp1의 발현이 증가되는 것을 확인하였고 TG2 발현억제로 인한 c-fos
와 NFATc1의 발현과 파골세포 증가현상은 Blimp1의 발현 억제를 통해 
그 현상이 감소 되는 것을 확인하였다.  
이러한 현상들이 마우스의 뼈에서도 관찰 되는지 알아보기 위해 TG2 결
핍 마우스의 뼈를 이용하여 뼈 지표인자를 분석한 결과 TG2가 결핍된 마
우스에서 뼈의 양이 감소된 것을 확인하였고 뼈 조직염색법을 이용하여 파
골세포의 수와 면적은 증가되어있는 것을 관찰하였다.  
따라서 이러한 결과를 통해 TG2가 Blimp1을 통해 파골세포 분화와 기능
을 억제하는 역할을 한다는 것을 알 수 있었다. 
주요어 : 파골세포 분화, Transglutaminase 2, c-fos, NFATc1, 
 NF-κB, Blimp1 
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